Drug intelligence / Profile preview

PF-04629991

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

PF-04629991 is an orally administered small molecule drug developed by Pfizer. It acts as a selective agonist of the sphingosine 1-phosphate receptor 1 (S1PR1), also known as S1P1. S1PR1 is a G protein-coupled receptor involved in immune cell trafficking and vascular integrity. By activating S1PR1, PF-04629991 modulates immune responses, which may have therapeutic potential in autoimmune diseases and other conditions where regulation of lymphocyte migration is beneficial[1][2][8]. The compound has been described as having a novel mechanism of action among S1P receptor modulators.

Targets

EDG1 (Sphingosine-1-phosphate receptors)

Beyond the preview

Go deeper on PF-04629991.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-04629991.

Explore the full profile